NCT05957380View on ClinicalTrials.gov

Clinical Study to Evaluate the Efficacy and Safety of DA-2803 in Chronic Hepatitis B Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 20, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

September 30, 2024

Conditions
Hepatitis B
Interventions
DRUG

DA-2803

All participants are administered one tablet per day for 48 weeks

DRUG

DA-2803-R

All participants are administered one tablet per day for 48 weeks

DRUG

Placebo of DA-2803

All participants are administered one tablet per day for 48 weeks

DRUG

Placebo of DA-2803-R

All participants are administered one tablet per day for 48 weeks

Trial Locations (1)

Unknown

The Catholic University of Korea, Seoul, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY